Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 70
  • Home
  • Print this page
  • Email this page
Year : 2015  |  Volume : 1  |  Issue : 2  |  Page : 84-91

Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer

1 Department of Oncology, Manipal Hospitals, Bengaluru, Karnataka, India
2 Department of Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India
3 Institutes of Cancer, Indraprastha Apollo Hospital, New Delhi, India
4 MIOT Institute of Cancer Cure, MIOT Hospitals, Chennai, Tamil Nadu, India
5 Department of Medical Affair, Roche Products (India) Pvt. Ltd., Mumbai, Maharashtra, India

Correspondence Address:
Siddharth Naik
1503, "The Capital", Plot No. C-70, Behind ICICI Bank, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2454-6798.173299

Rights and Permissions

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in improving the prognosis of these patients. Pertuzumab, a recombinant humanized monoclonal antibody and the first in a class of HER2 dimerization inhibitors approved for treating HER2+ breast cancer. It blocks ligand-dependent heterodimerization and ligand-independent homodimerization of HER2 with other HER members. When used in combination with trastuzumab and taxane, pertuzumab complements the action of trastuzumab and results in a comprehensive blockade of HER2 signaling pathway. This review article traces the development of pertuzumab from concept to its current use in HER2+ breast cancer treatment. A search of Medical Literature Published since 2007 was performed in PubMed using the keywords "pertuzumab," "HER2+ breast cancer," "HER2 targeted therapy," "metastatic breast cancer," and in search engines for ongoing trials with pertuzumab and incidence of cancer and breast cancer in India. A total of 35 publications and abstracts from the American Society of Clinical Oncology were selected for this review. Pertuzumab is approved in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ metastatic BC, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. The dual HER2 blockade of pertuzumab and trastuzumab is now accepted worldwide as a standard of care by various guidelines.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded172    
    Comments [Add]    

Recommend this journal